Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “C3 Glomerulopathy (C3G)”

25 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 25 results

Large-scale testing (Phase 3)Study completedNCT05067127
What this trial is testing

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 124
Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Large-scale testing (Phase 3)Looking for participantsNCT04817618
What this trial is testing

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Who this might be right for
C3G
Novartis Pharmaceuticals 98
Not applicableAvailableNCT05222412
What this trial is testing

Managed Access Programs for LNP023, Iptacopan

Who this might be right for
C3 Glomerulopathy (C3G)Paroxysmal Nocturnal Hemoglobinuria (PNH)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT03369236
What this trial is testing

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Who this might be right for
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Alexion Pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)Looking for participantsNCT06209736
What this trial is testing

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Who this might be right for
C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation 20
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50
Early research (Phase 1)Looking for participantsNCT07483827
What this trial is testing

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

Who this might be right for
C3 Glomerulopathy (C3G)Healthy Adult Participants
eleva GmbH 39
Not applicableApproved For MarketingNCT04729062
What this trial is testing

C3G/Primary IC-MPGN EAP

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05647811
What this trial is testing

Study of NM8074 in Adult C3 Glomerulopathy Patients

Who this might be right for
C3 Glomerulopathy
NovelMed Therapeutics 18
Testing effectiveness (Phase 2)Study completedNCT03301467
What this trial is testing

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Who this might be right for
C3 Glomerulopathy (C3G)
Amgen 57
Large-scale testing (Phase 3)Looking for participantsNCT03955445
What this trial is testing

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Who this might be right for
C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals 225
Large-scale testing (Phase 3)Active Not RecruitingNCT05809531
What this trial is testing

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 100
Early research (Phase 1)WithdrawnNCT02302755
What this trial is testing

TP10 Use in Patients With C3 Glomerulopathy (C3G)

Who this might be right for
Dense Deposit Disease
University of Iowa
Testing effectiveness (Phase 2)Study completedNCT04572854
What this trial is testing

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Who this might be right for
C3GIC-MPGNRenal Transplant+9 more
Apellis Pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07730632
What this trial is testing

Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

Who this might be right for
IgAN - IgA NephropathyImmune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 Glomerulopathy (C3G)+1 more
Qilu Pharmaceutical Co., Ltd. 60
Not applicableNot Yet RecruitingNCT07331259
What this trial is testing

CHART-C3G/CLNP023B12011

Who this might be right for
C3 GlomerulopathyComplement-mediated Kidney DiseaseProteinuria
Novartis Pharmaceuticals 83
Not applicableStudy completedNCT03723512
What this trial is testing

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Mario Negri Institute for Pharmacological Research 7
Testing effectiveness (Phase 2)Ended earlyNCT02682407
What this trial is testing

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Who this might be right for
IgANLNMN+1 more
Omeros Corporation 31
Not applicableLooking for participantsNCT07029542
What this trial is testing

Home Reported Outcomes in C3G Study

Who this might be right for
C3 Glomerulopathy
Novartis Pharmaceuticals 100
Next Page